Intl Fcstone Inc. Invests $788,000 in Celgene Co. (CELG)
Intl Fcstone Inc. purchased a new position in shares of Celgene Co. (NASDAQ:CELG) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,064 shares of the biopharmaceutical company’s stock, valued at approximately $788,000.
Other large investors have also recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the last quarter. Motco raised its stake in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares during the last quarter. Penserra Capital Management LLC acquired a new position in shares of Celgene during the 2nd quarter worth $129,000. Balentine LLC raised its stake in shares of Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 481 shares during the last quarter. Finally, Acropolis Investment Management LLC acquired a new position in shares of Celgene during the 2nd quarter worth $144,000. 80.16% of the stock is owned by institutional investors and hedge funds.
In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.95% of the company’s stock.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the company posted $1.58 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. sell-side analysts forecast that Celgene Co. will post 6.68 earnings per share for the current year.
CELG has been the subject of several research reports. BMO Capital Markets lifted their price target on Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, November 17th. Oppenheimer reaffirmed a “buy” rating and set a $170.00 price target on shares of Celgene in a research note on Friday, October 20th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price for the company in a research note on Monday, October 23rd. Cann reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene from an “underweight” rating to an “equal weight” rating in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. Celgene has an average rating of “Buy” and an average target price of $136.21.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/16/intl-fcstone-inc-invests-788000-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Stock Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related stocks with our FREE daily email newsletter.